Search Results
Aug 14, 2026, 14:19 ET Lttl Launches Groundbreaking Telehealth Site for Weight Loss, Longevity, and Wellness
Aug. 14, 2026 /PRNewswire/ -- Lttl is an all-new direct-to-consumer telehealth brand, specializing in personalized GLP-1 weight management, longevity protocols, and microdosed therapy.
More news about: Lttl
Aug 14, 2026, 11:44 ET Aurisco Pharmaceutical est le premier fabricant mondial d'oligonucléotides génériques à avoir passé avec succès l'inspection de l'USFDA
19 juin 2026), comme prévu initialement, et a porté sur la conformité aux bonnes pratiques de fabrication (BPFa) pour les oligonucléotides, les peptides GLP-1 (tels que le sémaglutide et le tirzépatide) et les petites molécules.Le rapport d'évaluation d'impact environnemental (EIR) a confirmé qu'Aurisco
More news about: Aurisco Pharmaceutical
Aug 12, 2026, 15:00 ET Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
Inclisiran Sodium inspection was carried out for 5 days (15-19.Jun.2026), as initially planned, and covered cGMP compliance inspection for oligonucleotides, GLP-1 peptides (such as Semaglutide and Tirzepatide) and small molecules.The EIR letter confirmed Aurisco successfully addressed the inspector's observations
More news about: Aurisco Pharmaceutical
Aug 12, 2026, 15:00 ET Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA
inspection was carried out for 5 days (15-19.Jun.2026), as initially planned, and covered cGMP compliance inspection for oligonucleotides, GLP-1 peptides (such as Semaglutide and Tirzepatide) and small molecules.The EIR letter confirmed Aurisco successfully addressed the inspector's
More news about: Aurisco Pharmaceutical
Aug 12, 2026, 09:00 ET U.S. News & World Report Releases Debut Ratings for the 2026-2027 Best GLP-1 Telehealth Platforms
Best GLP-1 Telehealth Platforms. The inaugural ratings evaluate 20 online platforms offering FDA-approved, brand-name GLP-1 medications – such as Wegovy, Zepbound, Ozempic and Foundayo – to help consumers
More news about: U.S. News & World Report, L.P.
Aug 12, 2026, 09:00 ET New study from CVS Caremark and Employee Benefit News shows how employers rely on their pharmacy benefit manager to create sustainable pharmacy solutions
Seventy-seven percent of employers say the high cost of GLP-1 coverage is a concern — with 80% having either already limited GLP-1 coverage for weight loss or considering limits.CVS Caremark is focused on improving affordability and access to GLP-1s by
More news about: CVS Health
Aug 12, 2026, 09:00 ET AirSculpt® Partners with Tiger Aesthetics™ in First National Partnership to Offer alloClae™
goals."As consumer demand for minimally invasive body contouring and body enhancement continues to grow, driven in part by the rise of GLP-1 medications and evolving aesthetic goals, AirSculpt is expanding its treatment portfolio to provide patients with more personalized solutions through
More news about: AirSculpt® Technologies, Inc.
Aug 12, 2026, 09:00 ET Rising Healthcare Costs Push Employers Toward Greater Benefits Oversight
cost of specialty drugs as a top healthcare cost challenge, reflecting the growing impact of high-cost therapies, including GLP-1 medications. Rather than shifting more costs to employees, organizations are focusing on greater transparency in pharmacy benefit manager (PBM)
More news about: Gallagher
Aug 12, 2026, 08:15 ET Employers with Claims Data Access Take More Action on Healthcare Costs, National Alliance of Healthcare Purchaser Coalitions Survey Finds
Emerging Priorities in GLP-1s, Mental Health, Equity and Women's HealthThe survey also finds employers moving toward more disciplined management, measurement and accountability in fast-evolving benefit areas. Employers covering or considering branded GLP-1 medications are more
More news about: National Alliance of Healthcare Purchaser Coalitions
Aug 12, 2026, 07:00 ET Healthcare CFOs Face a Wide Readiness Gap as Business Performance and AI Value Expectations Rise, Deloitte Survey Finds
outcomes more than proven financial results. Surveyed CFOs of only 18% of AI scalers consistently measure AI's impact financially.GLP-1 and specialty drug costs are another margin gap area for health plans: 85% of surveyed health plan finance leaders expect a moderate-to-major
More news about: Deloitte LLP
Aug 12, 2026, 05:59 ET Apotex Announces First Quarter 2027 Results
Company's semaglutide portfolio and positions Apotex to participate in the growing obesity treatment market while enhancing access to lower-cost GLP-1 therapies.In June 2026, Apotex launched generic sitagliptin tablets (generic Januvia) and sitagliptin/metformin tablets
More news about: Apotex Health Corp.
Aug 12, 2026, 03:00 ET BASF Agricultural Solutions stärkt Forschung durch Investition in neues Climate Center am Hauptsitz
wissenschaftliche Studien. Die Investition ist eine Antwort auf steigende regulatorische Anforderungen und die wachsende Nachfrage nach hochwertigen, GLP-konformen (Good Laboratory Practice) ökotoxikologischen Studien.„Das neue Climate Center ist weit mehr als eine Forschungseinrichtung. Es ist
More news about: BASF Agricultural Solutions
Aug 12, 2026, 03:00 ET BASF Agricultural Solutions invests in new Climate Center at its headquarters to strengthen research capabilities
scientific studies. The investment responds to increasing regulatory requirements and rising demand for high-quality, Good Laboratory Practice (GLP)-compliant ecotoxicology studies."The new Climate Center is much more than a research facility. It is a strategic investment that supports our ambition
More news about: BASF Agricultural Solutions
Aug 12, 2026, 03:00 ET BASF Agricultural Solutions invests in new Climate Center at its headquarters to strengthen research capabilities
scientific studies. The investment responds to increasing regulatory requirements and rising demand for high-quality, Good Laboratory Practice (GLP)-compliant ecotoxicology studies."The new Climate Center is much more than a research facility. It is a strategic investment that supports our ambition
More news about: BASF Agricultural Solutions
Aug 11, 2026, 13:59 ET Bergeson & Campbell, P.C. and LexisNexis Publish 2026 Edition of Guide to the Toxic Substances Control Act (TSCA)
Lara A. Hall, MS, RQAP-GLP; Senior Toxicologist and Regulatory Scientist
More news about: Bergeson & Campbell, P.C.
Aug 11, 2026, 09:55 ET Focus Health's Irving Health & Wellness Clinic Expands Its Medical Weight Loss Program, which includes Semaglutide and Tirzepatide, to include multiple new wellness treatments
The Irving, Texas clinic now pairs its GLP-1 weight loss program with a bigger menu of aesthetic treatments, including Botox, dermal fillers, and microneedling. Every visit is handled by licensed medical providers, and the clinic serves Las Colinas, Valley Ranch, and the wider Dallas-Fort
More news about: Focus Health
Aug 11, 2026, 09:14 ET Ivim Health Named No. 38 on the 2026 Inc. 5000 List, the Most Prestigious Ranking of America's Fastest-Growing Private Companies
Anthony Kantor. "Patients can tell when someone is actually paying attention, and they stay when they feel it."Ivim Health started in GLP-1 weight care and applied the same care model to hormone health. It launched Women's Hormone Health in June 2026, built on HormoneIQ™, a proprietary
More news about: Ivim Health
Aug 11, 2026, 08:00 ET Novo Nordisk's Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US
type 2 diabetes, used in combination with a mealtime insulin or in combination with common oral anti-diabetic agents and/or GLP-1 receptor agonist, in three randomized, open-label, treat-to-target, active-controlled trials and one randomized, double-blind, treat-to-target,
More news about: Novo Nordisk
Aug 11, 2026, 06:35 ET As GLP-1 Medications Reshape America, Prime Cuts Beef Jerky Identifies a New Consumer Movement Driving the Rise of Gas Station Gourmet
energy, satiety, wellness, and performance rather than simply satisfying cravings this is the Real Food Movement.The GLP–1 effect is rewriting food culture, as the rising use of GLP–1 medications accelerates a shift toward higher–protein, nutrient–dense eating; healthcare professionals now emphasize
More news about: Prime Cuts Jerky
Aug 11, 2026, 06:30 ET DarioHealth Reports Second Quarter 2026 Financial Results
engagement to include provider-led care capabilitiesLaunched the first provider-backed offering, Dario's Integrated GLP-1 Program, combining the digital platform with GLP-1 medical evaluation, prescribing and oversightDarioIQ: The Engine UnderneathMore
More news about: DarioHealth Corp.
Aug 10, 2026, 14:37 ET ATS Corporation Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ATS Corporation (ATS)
ATS' release blamed the setbacks on a "combination of timing of project execution, a more normalized level of GLP-1-related activities compared to the prior-year period, and the impacts of the restructuring activities within the Company's transportation businesses."
More news about: Levi & Korsinsky, LLP
Aug 10, 2026, 13:01 ET Cuvo Health, the #1 White Label Telehealth Platform, Surpasses 300 Exclusive Providers Serving All 50 States
behind consumer health brands, med spas, wellness centers, and fitness practices nationwide. Operators launch a telehealth business offering GLP-1 weight loss, peptides, TRT, women's HRT, hair loss, ED treatment, concierge medicine, primary care, urgent care, mental health, and dermatology
More news about: Cuvo Health
Aug 10, 2026, 09:00 ET RxBenefits Releases Pharmacy Benefits Market Report to Help Benefits Advisors Evaluate Transparent PBMs
prescription claims account for more than 50% of total pharmacy spend, and a single specialty drug can add more than $250,000 per year to plan costs. GLP-1 medications illustrate the pressure: national spending on these drugs rose more than 500% between 2018 and 2023."Transparency is the price
More news about: RxBenefits
Aug 10, 2026, 07:00 ET 歌禮宣布在美國啟動兩項治療肥胖症的I期研究：胰澱素受體激動劑多肽月注射劑ASC36、ASC36和GLP-1R/GIPR激動劑多肽ASC35的復方月注射劑ASC36_35FDC
Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款每日一次口服小分子GLP-1R激動劑，用於長期體重管理和糖尿病治療；ASC30_48FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC48（GIPR激動劑）的固定劑量復方制劑；ASC30_48_39FDC，一款每日一次口服小分子三靶點激動劑，為ASC30（GLP-1R激動劑）、ASC48（GIPR激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC39，一款與eloralintide類似、強效且對胰澱素具有選擇性的每日一次口服小分子胰澱素受體激動劑（SARA）；ASC30_39FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC36，一款胰澱素多肽，設計為每月一次至每季度一次皮下注射以及每日一次口服；ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FDC，一款每月一次皮下注射四靶點激動劑多肽，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。
More news about: 歌禮製藥有限公司
Aug 10, 2026, 07:00 ET Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be
More news about: Ascletis Pharma Inc.